Cluster headache supplement protocol — what the evidence actually supports
Cluster headache is among the most painful conditions in medicine — strictly unilateral, periorbital, with autonomic features (tearing, conjunctival injection, ptosis, rhinorrhoea), often clock-strikingly periodic. Standard management belongs to neurology: high-flow oxygen 12–15 L/min for acute attacks, subcutaneous sumatriptan, intranasal triptans or zolmitriptan, and verapamil titrated up to high doses for prevention, with steroid bridging during a cycle. Newer options include galcanezumab (CGRP monoclonal, approved for episodic cluster) and non-invasive vagal nerve stimulation. The supplement layer is genuinely modest — only two ingredients have meaningful supporting evidence: high-dose vitamin D3 (Patrick protocol observational data) and melatonin (small RCTs, particularly for episodic cluster's circadian pattern).
What actually has trial evidence
Vitamin D3 (high-dose "anti-inflammatory" protocol)
10,000 IU/day with vitamin K2 100–200 µg and magnesium glycinate 400 mg; target 25-OH-D 60–80 ng/mL
The Patrick observational cohort and subsequent self-reported data from large cluster patient communities suggest meaningfully reduced attack frequency with the "anti-inflammatory" vitamin D regimen at the doses above. Mechanism is unclear; vitamin D modulates inflammatory pathways and may influence the hypothalamic generator implicated in cluster periodicity. Trial-level RCT evidence is limited, but the cohort signal is robust enough that many headache specialists now check 25-OH-D in cluster patients and supplement to high-normal targets. Monitoring 25-OH-D and serum calcium is essential at these doses.
Melatonin
10 mg at bedtime during active cycle; may reduce dose during remission
The Leone 1996 RCT (20 episodic cluster patients) showed reduced attack frequency with 10 mg melatonin nightly. Mechanism plausibly relates to the well-documented circadian features of cluster (attacks frequently occurring at the same time nightly), with melatonin secretion abnormalities documented in cluster patients. Generally well-tolerated; dose is substantially higher than the 0.3–1 mg used for circadian phase-shifting in sleep medicine. Discuss with prescriber if on other sedating medications.
Magnesium glycinate (cofactor)
400–600 mg elemental magnesium at bedtime
No cluster-specific RCT, but magnesium has Level B evidence in migraine prevention, is a cofactor in the vitamin D pathway (essential for the conversion of 25-OH-D to 1,25-(OH)2-D), and pairs well with the high-dose vitamin D protocol. Magnesium repletion is necessary for vitamin D to function correctly.
Riboflavin (vitamin B2) + CoQ10 (consider as migraine-overlap adjunct)
Riboflavin 400 mg morning; CoQ10 ubiquinol 100 mg t.i.d.
Mostly extrapolated from migraine literature; no cluster-specific RCT. May be worth a 12-week trial in patients with overlapping migraine features, mitochondrial-disease phenotype, or partial response to verapamil + vitamin D + melatonin.
Lifestyle and trigger management
Several environmental inputs reliably modulate cluster cycles or attacks; addressing them often yields larger gains than any oral supplement:
- Alcohol — potent acute trigger during an active cycle. Total avoidance during a cycle is standard.
- Sleep schedule consistency — irregular sleep is a documented trigger; cluster attacks often occur during REM. Maintain consistent wake time.
- High altitude or hypoxia — air travel and altitude exposure are common triggers; supplemental oxygen may be needed.
- Strong odours, solvents, volatile organics — common triggers in susceptible patients.
- Nitroglycerin and other nitric oxide donors — clear pharmacological triggers; sildenafil and amyl nitrite likewise.
- Daytime napping — particularly during a cycle; many patients learn to avoid afternoon naps because they trigger evening attacks.
- Smoking cessation — strongly associated with cluster; cessation does not always abort attacks but is supported.
What to skip
- "Cluster headache supplements" sold as natural alternatives to verapamil — none exists. Verapamil at adequate dose (often 360–720 mg/day, sometimes higher) is the prevention standard.
- Psilocybin or LSD self-medication without medical supervision — although there is research interest and small case series suggest cycle-aborting effects, self-medication poses legal and safety risks. Trials of low-dose psilocybin in cluster are ongoing.
- "Adrenal support" supplements — irrelevant to cluster pathophysiology.
- High-dose 5-HTP — no cluster evidence; serotonin syndrome risk with triptans.
- Generic feverfew without trial dose standardisation — feverfew has modest migraine evidence at best; nothing cluster-specific.
- Cannabis / CBD products marketed for cluster — anecdotal at best; no quality trial data, and some patients report worsening.
What to track
Maintain a cluster diary: attack timing, duration, severity (0–10), triggers, abortive medications used, oxygen response. The number of attacks per 24 hours during an active cycle is the primary efficacy endpoint for any adjunct. Reassess any supplement intervention at 6–8 weeks of consistent use within a cycle (if episodic) or quarterly (if chronic). Photograph or scan the diary at clinic visits — the longitudinal data is what distinguishes signal from noise.